In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement

被引：0
|
作者：
Betting, David J. [1 ]
Kafi, Kamran [1 ]
Yamada, Reiko E. [1 ]
Steward, Kristopher K. [1 ]
Olafsen, Tove [2 ]
Wu, Anna M. [2 ]
van Rooijen, Nico [3 ]
Timmerman, John M. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA
[3] Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, Amsterdam, Netherlands
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [1] In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+B-cell lymphoma
    Timmerman, J.
    Betting, D.
    Yamada, R.
    Hurvitz, S.
    Steward, K.
    Said, J.
    van Rooijen, N.
    Kafi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
    Hu, Weiguo
    Ge, Xiaowen
    You, Tao
    Xu, Ting
    Zhang, Jinyan
    Wu, Gongxiong
    Peng, Zhihai
    Chorev, Michael
    Aktas, Bertal H.
    Halperin, Jose A.
    Brown, Jennifer R.
    Qin, Xuebin
    CANCER RESEARCH, 2011, 71 (06) : 2298 - 2307
  • [3] Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
    Ge, Xiaowen
    Du, Yiqun
    Chen, Jianfeng
    Zhu, Na
    Yao, Jiamei
    Zhang, Xin
    Wang, Na
    Sun, Yujing
    Gao, Feng
    Hu, Weiguo
    Hou, Yingyong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
    Tsai, Ping-Chiao
    Hernandez-Ilizaliturri, Francisco J.
    Bangia, Naveen
    Olejniczak, Scott H.
    Czuczman, Myron S.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1039 - 1050
  • [5] Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
    Li, Huafei
    Zhang, Ge
    Jiang, Cheng
    Zhang, Fulei
    Ke, Changhong
    Zhao, He
    Sun, Yun
    Zhao, Mengxin
    Chen, Di
    Zhu, Xiandi
    Zhang, Li
    Li, Bohua
    Dai, Jianxin
    Li, Wei
    ONCOTARGET, 2015, 6 (27) : 24192 - 24204
  • [6] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [7] Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20+ follicular B-cell nonHodgkin's lymphoma
    Fischer, M
    Behr, I
    Grünwald, F
    Knapp, WH
    Trümper, L
    von Schilling, C
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2004, 43 (05): : 171 - 176
  • [8] Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
    Barth, M. J.
    Hernandez-Ilizaliturri, F. J.
    Mavis, C.
    Tsai, P.
    Gibbs, J. F.
    Czuczman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu, Lei
    Adams, Mary
    Carter, Troy
    Chen, Roger
    Muller, George
    Stirling, David
    Schafer, Peter
    Bartlett, J. Blake
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4650 - 4657
  • [10] Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
    Hayashi, Kazumi
    Nagasaki, Eijiro
    Kan, Shin
    Ito, Masaki
    Kamata, Yuko
    Homma, Sadamu
    Aiba, Keisuke
    CANCER SCIENCE, 2016, 107 (05): : 682 - 689
12345